Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
Get insights into the top gainers and losers of Monday's pre-market session. As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH patients on standard therapy.
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside Needham initiates coverage on NewAmsterdam Pharma with a Buy rating, highlighting the potential of its cholesterol-lowering drug, obicetrapib.
